Logo

Oncocyte: Jennifer Levin Carter

Aug 27, 2020

Oncocyte has appointed Jennifer Levin Carter to its board of directors. Carter is a healthcare executive, board member, and entrepreneur and was most recently VP and head of precision health at Integral Health. She has founded and served as CEO at healthcare companies including N-of-One, where she was CEO from 2008 to 2012 and chief medical officer from 2012 until its acquisition by Qiagen in 2019. In addition to her board appointment for Oncocyte, Carter serves as a director of DFP Healthcare Acquisitions and is on the board of directors of home healthcare firm HouseWorks, digital health company eCaring, and the Target Cancer Foundation. She is a founding strategic board member of XSphera Biosciences, and on the directors advisory board at Smilow Cancer Hospital at Yale University. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.